Search

Displaying results 1621 - 1630 of 1723 in total
  1. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.

  2. Drug

    Glasdegib

    go.drugbank.com/drugs/DB11978
    ApprovedInvestigational

    [A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML).

  3. Drug

    SYNB1020

    go.drugbank.com/drugs/DB17667
    Investigational

    It was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer

  4. Drug

    Carbon monoxide

    go.drugbank.com/drugs/DB11588
    ApprovedInvestigational

    Since 2002, FDA has favorably reviewed three GRAS notifications for carbon monoxide use in fresh meat packaging [L2537]. … The FDA classifies this drug as permitted as a food additive in the packaging and preparation of food products, while following the federal code of regulations [L2531].

  5. Drug

    Filgrastim

    go.drugbank.com/drugs/DB00099
    ApprovedInvestigational

    [A245858] Tbo-filgrastim was approved by the FDA on August 29, 2012.[L36325] Filgrastim-sndz was approved on March 6, 2015 [L40768] and filgrastim-ayow was approved on March 2, 2022.

  6. Drug

    Sugemalimab

    go.drugbank.com/drugs/DB16641
    ApprovedInvestigational

    The antibody has also been granted the Breakthrough Therapy Designation by the FDA to treat relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) and an orphan drug designation

  7. Drug

    Ciltacabtagene autoleucel

    go.drugbank.com/drugs/DB16738
    ApprovedInvestigational

    [A245854] Carvykti was first approved by the FDA in February 2022 for the treatment of relapsed or refractory multiple myeloma in treatment-experienced patients.[L40744]

  8. Drug

    Elivaldogene autotemcel

    go.drugbank.com/drugs/DB16746
    Approved

    [L40298] In September 2022, Skysona was approved by the FDA.[L43247]

  9. Drug

    Azilsartan medoxomil

    go.drugbank.com/drugs/DB08822
    ApprovedInvestigational

    Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011.

  10. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    [A261831] Etrasimod was approved on October 13, 2023, by the FDA under the brand name VELSIPITY for the treatment of adults with moderately to severely active ulcerative colitis.